Edwards Lifesciences Corp... (EW)
| Bid | 69.59 |
| Market Cap | 40.8B |
| Revenue (ttm) | 5.72B |
| Net Income (ttm) | 4.17B |
| EPS (ttm) | 2.34 |
| PE Ratio (ttm) | 29.77 |
| Forward PE | 29.66 |
| Analyst | Hold |
| Ask | 69.75 |
| Volume | 990,386 |
| Avg. Volume (20D) | 5,153,583.6 |
| Open | 69.97 |
| Previous Close | 69.40 |
| Day's Range | 69.36 - 70.28 |
| 52-Week Range | 58.93 - 95.25 |
| Beta | 1.15 |
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the P...
Analyst Forecast
According to 20 analyst ratings, the average rating for EW stock is "Hold." The 12-month stock price forecast is $76.5, which is an increase of 9.82% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call TranscriptEdwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovig...
